

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

CONFIRMATION NO. 2221

SERIAL NUMBER 10/565,322	FILING or 371(c) DATE 01/20/2006	CLASS 424	GROUP ART UNIT 1614	ATTORNEY DOCKET NO. PHARMA-101		
APPLICANTS Evangelos Karavas, Agios Dimitrios Attikis, GREECE; Konstantinos Lioumis, Keratea, GREECE; Stavros Politis, Athens, GREECE;						
** CONTINUING DATA ***** This application is a 371 of PCT/GR04/00039 07/23/2004						
** FOREIGN APPLICATIONS ***** EUROPEAN PATENT OFFICE (EPO) 03386019.8 07/30/2003						
** IF REQUIRED, FOREIGN FILING LICENSE GRANTED ** * SMALL ENTITY ** 05/09/2006						
Foreign Priority claimed <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No 35 USC 119(a-d) conditions met <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Verified and /SAVITHA M RAO/ Acknowledged Examiner's Signature		<input type="checkbox"/> Met after Allowance Initials	STATE OR COUNTRY GREECE	SHEETS DRAWINGS 0	TOTAL CLAIMS 23	INDEPENDENT CLAIMS 1
ADDRESS AKC PATENTS 215 GROVE ST. NEWTON, MA 02466 UNITED STATES						
TITLE Sustained release formulation for venlafaxine hydrochloride						
FILING FEE RECEIVED 525	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:			<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		